vardenafil
Trade name: levitra
Approved
Aug 19, 2003
Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP. — NCATS
Clinical trial activity
72 trials · 32 clinical orgs · 11 marketing orgs
Earliest trial started Oct 1, 2002 (NCT00656188)
Timeline
2000s
2010s
- May 3, 2012
Teva — Marketing Organization
- Jun 5, 2015
Macleods Pharmaceuticals, Ltd — Marketing Organization
- Mar 17, 2016
Par Pharmaceuticals — Marketing Organization
- Mar 17, 2016
Bristol-Myers Squibb — Marketing Organization
- Oct 31, 2018
Amneal Pharmaceuticals — Marketing Organization
- Oct 31, 2018
Crossmedika Sa — Marketing Organization
- Oct 31, 2018
Zydus Discovery DMCC — Marketing Organization
- Oct 31, 2018
Jerome Stevens Pharmaceuticals — Marketing Organization
- Nov 16, 2018
Alembic — Marketing Organization
- Oct 22, 2019
Neogen — Marketing Organization
Indications
Approved for
Studied for
- Acquired Immunodeficiency Syndrome · Phase 4
- Brain Neoplasms · Early Phase 1
- Cystic Fibrosis · Phase 2
- Depression · Phase 3
- Diabetes Mellitus · Phase 3
- Diabetes Mellitus, Type 2 · Phase 2
- Endothelial Cells · Phase 4
- Erectile Dysfunction · Phase 4
- Fibrosis · Phase 4
- Genetic Diseases, Inborn · Phase 1
- Glioma · Early Phase 1
- Healthy Volunteers · Phase 1
- Hypertension · Phase 4
- Hypertension, Pulmonary · Phase 3
- Hypogonadism · Phase 4
- Metabolic Syndrome · Phase 4
- Neoplasm Metastasis · Early Phase 1
- Pharmacokinetics · Phase 1
- Prostatic Hyperplasia · Phase 2
- Prostatic Neoplasms · Phase 3
- Pulmonary Arterial Hypertension · Phase 4
- Raynaud Disease · Phase 2/Phase 3
- Reperfusion Injury · Phase 1
- Safety · Phase 4
- Sexual Dysfunction, Physiological · Phase 4
- Spinal Cord Injuries · Phase 4
- Tinnitus · Phase 2
- Urinary Bladder · Phase 2
- Urinary Bladder, Overactive · Phase 2
Mechanism of action
- Phosphodiesterase 5AINHIBITOR
PDE5A inhibitor
Selective
Approval history
- approvedAug 19, 2003
Chemistry & pharmacology
SMILES
CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12- Mol. weight
- 488.61 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1520 ↗
- WikipediaVardenafil ↗
- NCATSUCE6F4125H ↗
- ChEMBLCHEMBL1339 ↗
Also known as
- 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1h)-one
- 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1h)-one
- levitra
- levitra
- levitra
- levitra
- levitra
- staxyn
- staxyn
- vardenafil
- vardenafil
- vardenafil
- vardenafil
- vardenafil
- vardenafil
- vardenafil
- vardenafil
- vardenafil
- vardénafil
- vardénafil
- vardenafil dihydrochloride
- vardenafil dihydrochloride
- vardenafil hcl
- vardenafil hcl
- vardenafil hcl
- vardenafil hydrochloride
- vardenafil hydrochloride
- vardenafil hydrochloride
- vardenafil hydrochloride
- vardenafil hydrochloride hydrate
- vardenafil hydrochloride trihydrate
- vardenafilum
- vardenafilum
- vivanza
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06491108 | Phase 3 | Jun 1, 2024 | Tanta University |
| NCT04266197 | Phase 2 | Mar 31, 2020 | Argint International, Precision Medicine, Respira Therapeutics, Inc. |
| NCT05343637 | Phase 2 | Jul 30, 2019 | Respira Therapeutics, Inc. |
| NCT05567367 | Phase 1 | Jul 31, 2018 | Respira Therapeutics, Inc. |
| NCT03102398 | Phase 1/Phase 2 (Phase 2) | May 8, 2017 | A2 Healthcare Taiwan Corporation, Tritech Biopharmaceuticals Co., Ltd. |
| NCT01649739 | Phase 4 | Sep 1, 2012 | Tel Aviv University |
| NCT02344823 | Phase 4 | Jun 1, 2012 | University of Vienna |
| NCT02450188 | Phase 4 | Mar 1, 2012 | University of Florence |
| NCT01002534 | Phase 2 | Oct 1, 2011 | Université catholique de Louvain |
| NCT01406535 | N/A | Jul 29, 2011 | University of Vienna |
| NCT01348880 | Phase 1 | May 1, 2011 | Bayer, GlaxoSmithKline, Merck |
| NCT02279992 | Early Phase 1 (Phase 1) | May 1, 2011 | Cedars-Sinai Medical Center |
| NCT01260285 | Phase 1 | Dec 1, 2010 | Department of Veteran Affairs, McGuire Research Institute |
| NCT01168817 | Phase 2 | Aug 1, 2010 | Bayer |
| NCT01063855 | Phase 3 | Apr 1, 2010 | Johnson and Johnson |
| NCT02219646 | Phase 2 | Mar 1, 2010 | University of Modena and Reggio Emilia |
| NCT01110590 | Phase 1 | Jan 1, 2010 | Bayer |
| NCT01084187 | Phase 4 | Jan 1, 2010 | Rio de Janeiro State University |
| NCT00738400 | Phase 4 | Nov 1, 2008 | Bayer |
| NCT00705588 | Phase 4 | Aug 1, 2008 | Tel Aviv University |
Organizations
Research & Development (32)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 48 | 47 | 4 | 2002 |
| GlaxoSmithKline | For profit | 19 | 1 | 3 | 2002 |
| Respira Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2018 |
| Schering-Plough | For profit | 2 | 0 | 1 | 2008 |
| Tel Aviv University | Academic/Hospital | 2 | 2 | 1 | 2008 |
| University of Vienna | Academic/Hospital | 2 | 2 | 2 | 2011 |
| A2 Healthcare Taiwan Corporation | For profit | 1 | 0 | 1 | 2017 |
| Amgen | For profit | 1 | 0 | 1 | 2003 |
| Argint International | For profit | 1 | 0 | 1 | 2020 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 1 | 1 | 2011 |
| China Rehabilitation Research Center | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Chinese University of Hong Kong | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2010 |
| Government of Hong Kong | Government | 1 | 1 | 1 | 2006 |
| Hospital Santa Fe | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Inje University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Israel Urology Association | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2010 |
| McGuire Research Institute | Academic/Hospital | 1 | 1 | 1 | 2010 |
Marketing (14)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alembic | For profit | MKTG | Nov 16, 2018 |
| Alembic | For profit | SYN | Nov 16, 2018 |
| Amneal Pharmaceuticals | For profit | MKTG | Oct 31, 2018 |
| Bayer | For profit | SYN | Aug 19, 2003 |
| Bayer | For profit | NDA | Aug 19, 2003 |
| Bristol-Myers Squibb | For profit | MKTG | Mar 17, 2016 |
| Crossmedika Sa | For profit | MKTG | Oct 31, 2018 |
| Jerome Stevens Pharmaceuticals | For profit | MKTG | Oct 31, 2018 |
| Macleods Pharmaceuticals, Ltd | For profit | MKTG | Jun 5, 2015 |
| Neogen | For profit | MKTG | Oct 22, 2019 |
| Par Pharmaceuticals | For profit | MKTG | Mar 17, 2016 |
| Teva | For profit | MKTG | May 3, 2012 |
| Teva | For profit | SYN | Jul 12, 2017 |
| Zydus Discovery DMCC | For profit | MKTG | Oct 31, 2018 |